Janssen And ViiV: Giving HIV/AIDS Patients Options Is Key
Executive Summary
With EU submissions for once-monthly long-acting anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.
You may also be interested in...
ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients
The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.
ViiV Two-Drug HIV Pill Juluca Close To Europe Okay
The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.